RYTM Company Profile and Key Details

Q: Who are the executives of RYTM?

Mr. Hunter C. Smith M.B.A.Chief Financial Officer & TreasurerMs. Jennifer L. ChienExecutive Vice President & Head of North AmericaMr. Joseph ShulmanChief Technical OfficerDr. David P. Meeker M.D.Chairman, Pres & Chief Executive OfficerMr. David ConnollyHead of Investor Relations & Corporation CommunicationsMr. Christopher GermanCorporation Controller, Principal Accounting Officer & Executive DirectorMr. Yann MazabraudExecutive Vice President & Head of InternationalMs. Pamela J. CramerChief HR OfficerMr. Jim FlahertySenior Vice President & Gen. CounselMs. Sarah RyanVice President of Sales & MarketingMr. William T. RobertsChief Accounting Officer

NASDAQ : RYTM

Rhythm Pharmaceuticals

$101.39

4.6+4.75%

At Close 4:00 PM

60.71

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Rhythm Pharmaceuticals, Inc. (RYTM) stock surged +4.75%, trading at $101.39 on NASDAQ, up from the previous close of $96.79. The stock opened at $97.90, fluctuating between $97.44 and $102.05 in the recent session.

Stock Snapshot

96.79

Prev. Close

6.95B

Market Cap

97.44

Day Low

-32.39

P/E Ratio

-3.13

EPS (TTM)

-2.32

Cash Flow per Share

97.9

Open

68.59M

Number of Shares

102.05

Day High

82.51%

Free Float in %

2.87

Book Value

1.23M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	97.80	102.14	97.44	101.39	1.25M
Jun 18, 2026	97.56	99.95	95.97	96.79	1.56M
Jun 17, 2026	89.82	96.11	89.82	95.83	1.74M
Jun 16, 2026	90.94	91.96	88.53	89.72	609.51K
Jun 15, 2026	93.75	98.37	89.03	89.70	2.23M
Jun 12, 2026	87.65	90.16	87.65	88.38	553.36K
Jun 11, 2026	85.61	89.08	84.90	87.66	683.97K
Jun 10, 2026	87.88	92.35	85.57	85.71	851.95K
Jun 09, 2026	87.65	90.14	84.73	87.86	626.44K
Jun 08, 2026	87.09	87.10	84.88	85.93	483.15K
Jun 05, 2026	87.74	89.33	85.44	86.40	417.78K
Jun 04, 2026	85.36	89.13	85.05	87.61	392.93K
Jun 03, 2026	84.29	85.94	83.89	84.71	408.89K
Jun 01, 2026	87.92	89.05	86.00	87.87	468.23K
May 29, 2026	93.13	93.50	87.98	88.32	730.41K
May 28, 2026	91.50	93.31	90.44	92.98	549.03K
May 27, 2026	89.72	92.33	89.42	91.42	495.68K
May 26, 2026	88.79	90.78	87.84	89.82	322.67K
May 22, 2026	89.66	90.90	87.75	87.84	479.07K
May 21, 2026	89.53	92.13	88.92	90.19	539.53K

Contact Details

Boston, MA 02116

United States

https://www.rhythmtx.com 857 264 4280

About Company

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) closed at $101.39 USD, gaining $4.60 (4.75%) from the previous close of $96.79. The stock is currently mid-range between its 52-week high and low $60.80 and $122.20. With a market capitalization of about $6.95 billion, Rhythm Pharmaceuticals, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.92). Key stats such as the average daily volume over the past year has been around 790.37 thousand shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Rhythm Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Meeker, the company employs approximately 283 people and listed since October 09, 2017. Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -3.73%, SMA50 -6.48%, SMA200 4.54%). The stock’s 14-day RSI is 43.68 (neutral), while the ATR of 5.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.75% below its high and over 113.64% above its low. Average 10-day trading volume of 1.48 million shares is significantly above the 3-month average of 803.74 thousand, indicating heightened recent market interest.

Valuation Metrics

Rhythm Pharmaceuticals, Inc. trades at a P/E ratio of -31.62, slightly below the S&P 500 average, with a price-to-sales ratio of 31.26 and a price-to-book ratio of 54.74 reflecting a rich premium to book value. The P/FCF stands at -56.36, also below market averages. Compared to sector medians, Rhythm Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Rhythm Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$24.16. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Rhythm Pharmaceuticals, Inc. generated EPS of -$3.10 over the past year. Five-year average earnings growth is -2.34%. The latest quarter delivered EPS of -$0.83. The next quarter is forecast at -$0.80. Next year's EPS is expected at $30.68. Analyst sentiment is bullish. Analyst rating data shows there are 23 Strong Buy ratings, 32 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $176.00 to $84.00. The high target offers 73.59% upside. The low target suggests -17.15% downside. The mean target is $130.91. This offers 29.12% upside. Rhythm Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -3.49%. The prior quarter beat by -7.59%. Over the last six quarters, Apple has recorded several small beats. These include 4.35% in February 26, 2025.

Shareholding & Insider Activity

Rhythm Pharmaceuticals, Inc. has 66.42 million shares outstanding. The public float is 54.80 million shares, elevated short interest at 9.03% of float. This equals 4.67 million shares. The short ratio is 7.76 days. Institutional investors hold 110.82% of the float. Insiders own 0.77%. RA CAPITAL MANAGEMENT, L.P. holds 4.36 million shares, Foley Todd has 909.26 thousand shares and Meeker David P has 201.82 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.47 thousand shares across 9 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Rhythm Pharmaceuticals generated $77.43M in revenue, or $1.34 per share. Gross margin was 87.99%, operating margin -238.10%, and net profit margin -238.52%. Returns are negative, with ROA at -55.50% and ROE at -108.79%.
On valuation metrics, Rhythm Pharmaceuticals trades at a P/E of -31.62, P/S of 31.26 and P/B of 54.74. The current ratio is 4.17 and quick ratio is 3.89. Operationally, the company’s inventory turnover is 0.80 and cash conversion cycle is 316.96 days. Debt-to-equity is 1.85, supported by a cash flow-to-debt ratio of -0.53.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Rhythm Pharmaceuticals posted revenue of $77.43M, down slightly from $23.64M in the prior quarter. Gross profit was $68.13M (margin 87.99%). Operating income was - $184.36M (margin -238.1%). Net income was- $184.68M (EPS - $3.20).
The company ended the quarter with $275.85M in cash and short-term investments, a total debt of $1.26M, and net debt of - $58.82M. Total assets were $332.75M, with equity of $169.76M. Financials further reflected weakness, with operating cash flow of - $136.16M, free cash flow of - $136.20M, and capital expenditures of - $47.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Rhythm Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.13%, with price expected at $101.52 by July 06, 2026, within a range of $96.97 to $106.32 3-Month Outlook: Projected rise of 35.88%, reaching $137.77 by September 18, 2026, with a range of $136.35 to $139.58. 1-Year Outlook: Projected gain of 27.03%, with price at $128.80 by June 22, 2027, within a range of $125.20 to $132.66.

Key Takeaways

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shares are flat -4.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Rhythm Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -31.62. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $90.55, suggesting -10.69% downside. Our AI forecast model points to short-term strength (0.13% over two weeks), a medium-term rise (35.88% over three months), and a longer-term gain (27.03% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Rhythm Pharmaceuticals, Inc. (RYTM) stock price?

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock price is $101.39 in the last trading session. During the trading session, RYTM stock reached the peak price of $102.05 while $97.44 was the lowest point it dropped to. The percentage change in RYTM stock occurred in the recent session was 4.75% while the dollar amount for the price change in RYTM stock was $4.60.

RYTM's industry and sector of operation?

The NASDAQ listed RYTM is part of Biotechnology industry that operates in the broader Healthcare sector. Rhythm Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RYTM?

Mr. Hunter C. Smith M.B.A.
Chief Financial Officer & Treasurer
Ms. Jennifer L. Chien
Executive Vice President & Head of North America
Mr. Joseph Shulman
Chief Technical Officer
Dr. David P. Meeker M.D.
Chairman, Pres & Chief Executive Officer
Mr. David Connolly
Head of Investor Relations & Corporation Communications
Mr. Christopher German
Corporation Controller, Principal Accounting Officer & Executive Director
Mr. Yann Mazabraud
Executive Vice President & Head of International
Ms. Pamela J. Cramer
Chief HR Officer
Mr. Jim Flaherty
Senior Vice President & Gen. Counsel
Ms. Sarah Ryan
Vice President of Sales & Marketing
Mr. William T. Roberts
Chief Accounting Officer

How RYTM did perform over past 52-week?

RYTM's closing price is 66.76% higher than its 52-week low of $60.80 where as its distance from 52-week high of $122.20 is -17.03%.

How many employees does RYTM have?

Number of RYTM employees currently stands at 283.

Link for RYTM official website?

Official Website of RYTM is: https://www.rhythmtx.com

How do I contact RYTM?

RYTM could be contacted at phone 857 264 4280 and can also be accessed through its website. RYTM operates from 222 Berkeley Street, Boston, MA 02116, United States.

How many shares of RYTM are traded daily?

RYTM stock volume for the day was 1.23M shares. The average number of RYTM shares traded daily for last 3 months was 790.37K.

What is the market cap of RYTM currently?

The market value of RYTM currently stands at $6.95B with its latest stock price at $101.39 and 68.59M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	283
Beta	1.92
Sales or Revenue	$77.43M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RYTM Company Profile and Key Details

Rhythm Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways